Images List Premium Download Classic

Immune Response

Immune Response-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Recombinant self-replicating polycistronic rna molecules
Glaxosmithkline Biologicals, Sa
November 30, 2017 - N°20170342442

This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed ...
Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer ...
Immatics Biotechnologies Gmbh
November 30, 2017 - N°20170342125

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Contructs for enhancing immune responses
The Wistar Institute Of Anatomy And Biology
November 30, 2017 - N°20170340730

Chimeric protein constructs including a herpesvirus glycoprotein d (gd) and a heterologous polypeptide that interact with herpes virus entry mediator (hvem) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment for cutaneous t cell lymphoma
3m Innovative Properties Company
November 30, 2017 - N°20170340612

The present invention provides method for treating a patient with cutaneous t cell lymphoma (ctcl). Generally, the methods include administering to the patient an irm compound in an amount effective to ameliorate at least one symptom or clinical sign of ctcl. In some embodiments, the methods also include administering to the patient a priming dose of a type i interferon. ...
Compositions and methods for treating clostridium difficile infection
University Of Virginia Patent Foundation
November 23, 2017 - N°20170334994

Clostridium difficile is the most common hospital acquired pathogen in the united states, and infection is in many cases fatal. Toxins a and b are its major virulence factors, but increasingly a third toxin may be present, known as c. Difficile transferase (cdt). An adp-ribosyltransferase that causes actin cytoskeletal disruption, cdt is typically produced by the major, hypervirulent strains and ...
Immunogenic wt-1 peptides and methods of use thereof
Memorial Sloan Kettering Cancer Center
November 23, 2017 - N°20170334951

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt-1-expressing cancer, comprising peptides derived from the wt-1 protein.
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Poxviral vaccines
Glaxosmithkline Biologicals, Sa
November 23, 2017 - N°20170333550

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
Size tunable microbial mimetics for immunotherapy of cancer
Glaxosmithkline Biologicals, Sa
November 23, 2017 - N°20170333542

The mm exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The mm constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo.
Target peptides for immunotherapy and diagnostics
The University Of Birmingham
November 23, 2017 - N°20170333541

A set of target peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e. G., cancer, (b) to function as immunotherapeutics in adoptive t cell therapy or as a vaccine, (c) facilitate antibody recognition ...
Koc1-derived peptide and vaccine including same
Oncotherapy Science, Inc.
November 23, 2017 - N°20170333476

The present invention provides koc1-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls. The present invention also provides compositions and pharmaceutical compositions containing them as ...
Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound ...
The Catholic University Of Korea Industry-academic Cooperation Foundation
November 23, 2017 - N°20170333370

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of il-17 and tnf-α, which are inflammatory cytokines, increases the activity of regulatory t cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune ...
Cross-protective pathogen protection, methods and compositions thereof
The Catholic University Of Korea Industry-academic Cooperation Foundation
November 16, 2017 - N°20170327565

The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved ...
Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
Bavarian Nordic A/s
November 16, 2017 - N°20170326228

Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an ...
Immune Response Patent Pack
Download 464+ patent application PDFs
Immune Response Patent Applications
Download 464+ Immune Response-related PDFs
For professional research & prior art discovery
inventor
  • 464+ full patent PDF documents of Immune Response-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Non-lipidated variants of neisseria meningitidis orf2086 antigens
Wyeth Llc
November 16, 2017 - N°20170326222

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated orf2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an orf2086 subfamily b polypeptide from serogroup b neisseria meningitidis, and methods related thereto.
Peptide mixture
Targovax Asa
November 16, 2017 - N°20170326218

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein. Each of the first and second peptides comprises a region of at least 8 amino acids which includes position 13 of the ras protein. Each of said regions of the first and second ...
Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
The Texas A&m University System
November 09, 2017 - N°20170321285

The invention pertains to biomarkers for identifying a cancer that is likely or not likely to evade the immune system of a subject, thus, is likely or not likely to show better prognosis (prognostic biomarker) and/or better responses to cancer therapies (predictive biomarker). The invention provides a method of identifying a subject as having a cancer that is likely ...
Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
Regeneron Pharmaceuticals, Inc.
November 09, 2017 - N°20170320948

The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation. The invention includes antibodies that bind cd3 and induce t cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific ...
Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
Novo Nordisk A/s
November 09, 2017 - N°20170320946

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed. Trem-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by ...
Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune ...
Academisch Ziekenhuis Leiden
November 09, 2017 - N°20170320915

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal t cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific cd8+ cytolytic cells ...
Methods and compositions for enhancing immune response
3m Innovative Properties Company
November 09, 2017 - N°20170319712

Methods and compositions for enhancing the immune response to an irm compound by depositing within a localized tissue region an irm depot preparation that provides an extended residence time of active irm within the localized tissue region.
Compositions and methods for self-adjuvanting vaccines against microbes and tumors
The Regents Of The University Of California
November 09, 2017 - N°20170319685

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide ...
Loading